Lydia Celine Tansem Buer

  • MD
  • +47 23 02 74 58

Education

MD University of Oslo (2012)

Current position

PhD student, Department of gastroenterology, Oslo University Hospital

 

Publications 2019

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML (2019)
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Scand J Gastroenterol, 54 (1), 41-48
DOI 10.1080/00365521.2018.1548646, PubMed 30650312

Publications 2018

Buer LCT, Høivik ML, Warren DJ, Medhus AW, Moum BA (2018)
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Inflamm Bowel Dis, 24 (5), 997-1004
DOI 10.1093/ibd/izx110, PubMed 29668901

Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW (2018)
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Scand J Gastroenterol, 53 (6), 692-699
DOI 10.1080/00365521.2018.1463391, PubMed 29852793

Publications 2017

Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML (2017)
Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study
J Crohns Colitis, 11 (3), 297-304
DOI 10.1093/ecco-jcc/jjw166, PubMed 27660339

Publications 2012

Buer LC, Hofmann BM (2012)
How does kidney transplantation affect the relationship between donor and recipient?
Tidsskr Nor Laegeforen, 132 (1), 41-3
DOI 10.4045/tidsskr.10.1403, PubMed 22240827

Page visits: 473